Clinical trial
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
NCT00325234 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00325234 |
|---|---|
| Title | Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer |
| Official title | A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Carboplatin, Gemcitabine, Vinorelbine |
| Enrollment | 135 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | May 12, 2006 |
| Last update posted | May 20, 2011 |
| Countries | Germany, Italy, South Africa, Spain, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: